Skip to main content
OpenTrials
Completed

NCT Number: NCT04810338

Study Evaluating the Pronostic Value of Vascular Refilling Rate on Mortality in Chronic Kidney Disease Patients on Dialysis

Aim of this study is to evaluate in a population of chronic kidney disease patients on dialysis (Stage 5D) during an observational period of 3 years:

* the prognostic value of vascular refilling rate on mortality and on the occurrence of i) cardiovascular events and ii) hospitalization number * the prognostic value of interdialytic weight gain on mortality and on the occurrence of i) cardiovascular events and ii) hospitalization number * the prognostic value of perdialytic weight loss on mortality and on the occurrence of i) cardiovascular events and ii) hospitalization number.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Chronic Kidney Diseases Chronic Disease Disease Attributes Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Kidney Diseases Male Urogenital Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Renal Insufficiency Renal Insufficiency, Chronic Urogenital Diseases Urologic Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Uhmontpellier

Montpellier, 34290, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Chronic Kidney Disease patient on dialysis (stage 5D) since at least september 2017 (3 months prior to study start date)
  • Anuric patient

Exclusion criteria

  • Chronic Kidney Disease patient on dialysis with residual kidney function

Treatment and study plan

Primary outcomes

  1. Prognostic value of vascular refilling rate on mortality

    Time frame: 2 years after inclusion

    The refilling rate will be assessed by the ratio of relative blood volume

  2. Prognostic value of vascular refilling rate on mortality

    Time frame: 3 years after inclusion

    The refilling rate will be assessed by the ratio of relative blood volume

  3. Prognostic value of vascular refilling rate on mortality

    Time frame: 3 years after inclusion

    The refilling rate will be assessed by the ratio UF max

  4. Prognostic value of vascular refilling rate on mortality

    Time frame: 2 years after inclusion

    The refilling rate will be assessed by the ratio UF max

Secondary outcomes

  1. Prognostic value of interdialytic weight gain

    Time frame: 2 years after inclusion

    Prognostic value of interdialytic weight gain

  2. Prognostic value of interdialytic weight gain

    Time frame: 3 years after inclusion

    Prognostic value of interdialytic weight gain

  3. Prognostic value of perdialytic weight loss

    Time frame: 2 years after inclusion

    Prognostic value of perdialytic weight loss

  4. Prognostic value of perdialytic weight loss

    Time frame: 3 years after inclusion

    Prognostic value of perdialytic weight loss

Interested in participating?

Completed

Looking for future studies?

Notify Me

Sponsors and collaborators

Lead sponsor

University Hospital, Montpellier

Other

Registry information

Official study title

Evaluation of the Pronostic Value of Vascular Refilling Rate on Mortality in Chronic Kidney Disease Patients on Dialysis (Stage 5D)

Acronym: REMVAMIR

Important dates

Study start
2018
Primary completion
2020
Study completion
2021
First posted
Mar 22, 2021
Registry last updated
Apr 14, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.